Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette's Disorder
NCT01416441Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in Tourette syndrome (TS), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Treatment Emergent Adverse Events, Clinically Significant Changes in Laboratory Parameter Values and 13 more. Started Oct 2011; status: completed.
02
Drugs
aripiprazole
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT01416441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416441.